Prostaglandin E1. Mechanisms of action and clinical potentialities


Cite item

Full Text

About the authors

A V Alferov

L V Aizenberg

References

  1. von Euler U. S. On the specific vasodilating and plain muscle stimulating substance from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J. Physiol. (Lond.) 1936; 88: 213-219.
  2. Варфоломеев С. Д. Простагландины - новый тип биологических регуляторов. Соросов, образоват. журн. 1996; 1: 40-47.
  3. Coleman R. A. Prostanoid receptors: their function and classification. In: Vane J., O'Grady J., eds. Therapeutic application of prostaglandins. London: Edward Arnold; 1993.
  4. Kerins D., Murray R., Fitzgerald G. Prostacyclin and prostaglandin E,: Molecular mechanisms and therapeutic utility. Progr. Hemostas. Thrombos. 199Г, 10: 307-337.
  5. Northup J. K., Smigel M. D., Sternweis P. C., Oilman A. G. The subunits of the stimulatory regulatory component of adenylate cyclase. Resolution of the activated 45000-dalton (alpha) subunit. J. Biol. Chem. 1983; 258: 11369-11376.
  6. Ney P., Feelisch M. Vasodilator effects pf PGE, in coronary and systemic circulation of the rat are mediated by ATH-sensitive potassium (K.+) channels. Agents and Action 1995; 45: 71-76.
  7. Anggard E., Larsson С. The sequence of the early steps in the metabolism of prostaglandin E, in man. Eur. J. Pharmacol. 1971; 14: 66-70.
  8. Cox J., Andreadis N., Bone R. Pulmonary extraction and pharmacokinetics of prostaglandin E, during continuous intravenous infusion in patients with adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1988; 137: 5-12.
  9. Piper P., Vane J., Wyllie J. Inactivation of prostaglandins by the lungs. Nature 1970; 225: 600-604.
  10. Мартынюк Т. В., Чазова И. Е., Масенко В. П. и др. Применение простагландина Е, в комбинации с антагонистом кальция иерадипином у больных с первичной легочной гипертензией. Кардиология 1997; 8: 4-9.
  11. Abe К., Sakakibara Т., Miyamoto Y., Ohnishi К. Effect of prostaglandin E, on pulmonary hypertension after protamine injection during cardiac surgery. J. Heart Lung Transplant. 1997; 16 (12): 1238-1247.
  12. Dagher E., Dumont L., Chartrand C., Blaise G. Effects of PGE, in experimental vasoconstrictive pulmonary hypertension. J. Heart Lung Transplant. 1993; 12 (2): 173-178.
  13. Iberer F., Wasler A., Tscheliessnigg K. et al. Prostaglandin E,induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. Anesthesiology 1992; 76 (5): 781-791.
  14. Sumiyoshi N., Kawachi S., Oishi K. et al. Effects of prostaglandin E, and dibutyryl cyclic AMP on hemodynamics after cardiopulmonary bypass in valve replacement surgery. J. Thorac. Cardiovasc. Surg. 1992; 103 (1): 33-39.
  15. Inoue S., Abe Т., Yamada A. et al. A case of pulmonary hypertensive crisis (PHC) treated with prostaglandin E, and tolazolin after surgery of ventricular septal defect in an adult. Zhonghua Nei Ke Za Zhi 1993; 32 (9): 591-593. 1
  16. Packer R., Stanek В., Hulsmann M. et al. Prostaglandin E, bridge to cardiac transplantation. Technique, dosage, results. Eur. Heart J. 1997; 18 (2): 318-329. Щ
  17. Schmid E. R., Biirki C., Engel M. et al. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. Anesth. and Analg. 1999; 89: 11081115.
  18. Tritapepe L., Voci P., Cogliati A. A. et al. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E, and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Eur. J. Cardiothorac. Surg. 1998; 14 (5): 494-502.
  19. Awan N. A., Evenson M. K., Needham K. E. et al. Cardiovasculatory and myocardial energetic effects of prostaglandin E, in severe left ventrical failure due to chronic coronary heart disease. Am. Heart J. 1981; 102: 703-709.
  20. Kunimoto F., Arai K., Isa Y. et al. A comparative study of the vasodilator effects of prostaglandin El in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome. Eur. Respir. J. 1997; 10 (5): 1084-1092.
  21. Pepke-Zaba J., Higgenboitam T. W., Dinh-Xuan A. T. et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173- 1174.
  22. Sitbon O., Brenot F., Denjean A. et al. Inhaled nitric oxide as screening vasodilatator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am. J. Respir. Crit. Care Med. 1995; 151: 384-389.
  23. Guo Z. H., Ye Y. Q., Jing B. W. Effects of different dosage of PGE1 in pulmonary arterial hypertension. J. Int. Med. Res. 1993; 21 (3): 161-164.
  24. Rabinowitz В., Schollmaer E., Weiss M. Prostaglandin El in heart disease: review and perspective. Am. J. Ther. 1997; 4: 353-358.
  25. Aral K. The intrapulmonary metabolism of prostaglandin El in patients with pulmonary hypertension. Kyobu Geka 1994; 47 (12): 1007-1011.
  26. Алекперов Р. Т., Мач Э. С., Гусева Н. Г. Лечение вазапростаном синдрома Рейно. Тер. арх. 1997; 8: 22-24.
  27. Кириченко А. А., Новикова Ю. Н. Эффективность вазапростана при артериальной недостаточности нижних конечностей. Ангиол. и сосуд, хир. 1997; 4: 43-49.
  28. Покровский А. В., Дан В. Н., Чупи А. В. и др. Вазапростан (простагландин Е,) в комплексном лечении критической ишемии нижних конечностей при атеросклеротическом поражении артерий. Ангиол. и сосуд, хир. 1996; 1: 63-72.
  29. Heidrich H. The importance of prostaglandin E, in peripheral arterial occlusive disease. Am. J. Ther. 1997; 4: 351-352.
  30. Menzoian J. O. Major leg amputations in patients with severe peripheral arterial occlusive disease (PAOD) not amenable to revascularisation procedures: results of randomized, placebocontrolled, multicenter study with alprostadi! (prostaglandin E,). In: Soc. Vase. Surg. Joint. Annual Meeting 1995; 15-22.
  31. Truebestein G., von Вагу S., Breddin К. et al. Intravenous prostaglandin E, versus pentoxifylline therapy in chronic arterial occlusive disease - a controlled randomised multicenter study. Vasa 1989; 28 (suppl.): 44-49.
  32. Adashi H., Sugihara H., Nakagawa H. et al. Effect of prostaglandin El on fractional distribution of cardiac output and organ blood flow in man: a simultaneous and non-invasive determination using double dose thallium-201 scintigraphy. Cardiovasc. Res. 1984; 18: 657-662.
  33. Siegel R. J., Shah P. K., Nathan M. et al. Prostaglandin E, infusion in unstable angina: effects on anginal frequency and cardiac function. Am. Heart J. 1984; 108: 836-868.
  34. De Servi S., Ktugman S., Chinonin R. et al. Prostaglandin E, administration in unstable angina patients undergoing PTCA: preliminary results. Eur. Heart J. 1990; 11: 2062.
  35. See J., Shell W., Mathews O. et al. Prostaglandin E, infusion after angioplasty in humans inhibits abrupt occlusion and early restenosis. Adv. Prostagland. Thromboxane Leukotr. Res. 1987; 17: 266-270.
  36. Shecier M., Agranat O., Har-Zahav Y. et al. Prostaglandin E, during angioplasty (PTCA) as preventive therapy of coronary restenosis. Am. J. Ther. 1997; 4: 395-400.
  37. Popat K. D., Pitt B. Hemodynamic effects of prostaglandin E, infusion in patients with acute myocardial infarction and left ventricular failure. Am. Heart J. 1982; 103: 485.
  38. Sharma В., Wyeth R. P., Gimenez H. J., Franciosa J. A. Intracoronary prostaglandin El plus streptokinase in acute myocardial infarction. Am. J. Cardiol. 1986; 58: 1161 - 1166.
  39. Sharma В., Wyeth R. P., Heinemann F. M., Bissett J. K. Addition of intracoronary prostaglandin El to streptokinase improves thrombolysis and left ventricular function in acute myocardial infarction. J. Am. Coll. Cardiol. 1988; 11 (suppl. 2): 104A.
  40. Goto F., Otani E., Kato S., Fujita T. Prostaglandin El as hypotensive drug during general anesthesia. Anaesthesia 1982; 37: 530-535.
  41. Okuda M., Ohi Y., Utsunomiya H. et al. Effects of prostaglandin El infusion during cardiopulmonary bypass. Masui 1989; 38 (8): 1036-1041.
  42. Sakuragi Т., Tanaka K., Dan K. et al. Continuous infusion of prostaglandin El facilitates weaning from cardiopulmonary bypass. Masui 1991; 40 (3): 343-348.
  43. Sakuragi Т., Shono S., Isino H. et al. Hypothermia after cardiopulmonary bypass in man: effects of prostaglandin El and phentolamine. Masui 1990; 39 (12): 1637-1645.
  44. van den Dungen J. J., Karliczek G. F., Brenken U. et al. The effect of prostaglandin El in patients undergoing clinical cardiopulmonary bypass. Ann. Thorac. Surg. 1983; 35 (4): 406- 414.
  45. Okuda M., Faruhashi K., Konishi K., Muneyuki M. Effects and arterial concentration of prostaglandin El during cardiopulmonary bypass. Eur. J. Anesthesiol. 1991; 8 (2): 129-134.
  46. Pitt B. R., Hammond G. L., Gillis С. N. Depressed pulmonary removal of [3H] prostaglandin El after prolonged cardiopulmonary bypass. J. Appl. Physiol. 1982; 52 (4): 887-892.
  47. Sato K., Ebine K., Tamura S. et al. The effects of prostaglandin El infusion during cardiopulmonary bypass on cardiac and renal function in the early postoperative period. Nippon Kyobu Geka Gakkai Zasshi 1994; 42 (3): 360-365.
  48. Bauer I., Dapper F., Demirakca S. et al. Perioperative management of pulmonary hypertension after heart transplantation in childhood. Anesth. Analg. 1997; 85 (3): 507-513.
  49. Krieg P., Wahlers Т., Giess W. et al. Inhaled nitric oxide and inhaled prostaglandin El: effect on left ventricular contractility when used for treatment of experimental pulmonary hypertension. Crit. Care Med. 1998; 26 (6): 103-109.
  50. D'Ambra M., LaRaia P., Philbin D. et al. Prostaglandin E,: a new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J. Thorac. Cardiovasc. Surg. 1985; 89: 567-572.
  51. Mikawa K., Maekawa N., Goto R. et al. Use of prostaglandin El to treat peri-anaesthetic pulmonary hypertension associated with mitral valve disease. Eur. Surg. Res. 1993; 25 (2): 65- 73.
  52. Ishicawa S., Hasegawa Т., Kato M. et al. Effects of prostaglandin E1 in the treatment of congestive heart failure after valve replacement. Kyobu Geka 1992; 45 (4): 329-334.
  53. Hirose M., Yoda K., Sakai K. et al. Prostaglandin El, as a vasodilator therapy, for low output syndrome after cardiac surgery. Kokyu To Junkan 1989; 37 (8): 915-917.
  54. Kieler-Jensen N., Lundin S., Ricksten S. E. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin El, and sodium nitroprusside. J. Heart Transplant. 1995; 14: 436-443.
  55. Фекс П. Анестезия и правый желудочек. В кн.: 10-й Всемирный конгресс анестезиологов. Гаага, Нидерланды, 10-12 июня 1992. Освежающий курс лекций. Архангельск; 1993. 176-180.
  56. Priebe H. J. Myocardial ischemia during vasodilator therapy in a canine model of pulmonary hypertension and coronary insufficiency. Anesthesiology 1992; 76 (5): 781-791.
  57. Adamson R. M., Dembitsky W. P., Jaski B. E. et al. Left ventricular assist device support of medically unresponsive pulmonary hypertension and aortic insufficiency. Am. Soc. Artific. Intern. Organs. J. 1997; 43 (4): 365-369.
  58. Peterzen В., Granfeldt H., Lonn U. et al. Management of patients with end-stage heart disease treated with in implatable left ventricular assist device in nontransplanting center. J. Cardiothorac. Vas. Anesth. 2000; 14 (4): 438-443.
  59. Rajek A., Pernerstofer Т., Kastner J. et al. Inhaled nitric oxide reduces pulmonary vascular resistance more than prostaglandin E(l) during heart transplantation. Anesth. Analg. 2000; 90 (3): 523-530.
  60. Armitage J., Hardesty R., Griffith B. Prostaglandin E,: An effective treatment of right heart failure after orthoptic heart transplantation. J. Heart Transplant. 1987; 6: 348-351.
  61. Fonger J., Borkon A., Baumgartner W. et al. Acute right ventricular failure following heart transplantation: Improvement with prostaglandin E, and right ventricular assist. J. Heart Transplant. 1986; 5: 317-321.
  62. Gornez-Arnau J., Planas A., Lora-Tamayo J. I., Martinez M. V. Special anesthesia care in heart transplantation. The management of right ventricular failure. Rev. Esp. Cardiol. 1995; 48 (7): 60-64.
  63. Frey В., Pacher R., Locker G. et al. Prognostic value of hemodynamic vs big endothelin measurements during long term therapy in advanced heart failure patients. Chest 2000; 117 (6): 1713-1719.
  64. Pacher R., Stanek B. Prostaglandin E. Z. Kardiol. 1999: 88 (3): 33-35.
  65. McKenna J. W., Swedberg F., Zannad H. et al. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: results of FIRST. Eur. Heart J. 1994; 15 (suppl.): 36.
  66. Sueta C. A., Cheorgiade M., Adams К. F. et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am. J. Cardiol. 1995; 75: 34A-43A.
  67. Radermacher P., Bantak P., Becker H., Falke K. J. Prostaglandin El and nitroglycerin reduce pulmonary capillary pressure but worsen ventilatory-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 1989; 70: 601-606.
  68. El-Gatit A., Al~Khaja N., Belboul A. et al. Influence of alprostadil on pulmonary dysfunction after a cardiac operation. Ann. Thorac. Surg. 1992; 53: 1018-1022.
  69. Walmrath D., Schermuly R., Pilch J. et al. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Int. J. Cardiol. 1996; 56 (2): 131-135.
  70. Putensen C., Hermann C., Kleinsasser A., Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E, and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1998; 157: 1743-1747.
  71. Freeman B. Free radical chemistry of nitric oxide: looking at the dark side. Chest 1994; 105: 79S-84S.
  72. Young E. UHC Clinical Practice Advancement Center. Technology report: nitric oxide therapy. Oak Brook, IL: UHC Services Corporation; 1996.
  73. Bocchi E. A., Baca F., Aulor J. O. Jr. et al. Inhaled nitric oxide leading to pulmonary edema in stable severe left heart failure. Am. J. Cardiol. 1994; 74: 70-72.
  74. Fierol L., Brunei F., Dhainaut T. F. et al. Effect of NO on right ventricular function in ARDS. Am. J. Respir. Crit. Care Med. 1999; 151: 1414-1419.
  75. Hare J. M., Sherman S. K., Body S. С. et al. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation 1997; 95: 2250-2253.
  76. Loh E., Stamker J. S., Loscalzo J., Colucci W. S. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780-2785.
  77. Hare J. M., Loh Е., Greager M. A., Colucci W. S. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995; 92: 2198-2203.
  78. Hayward С. S., Kalnins W. V., Rogers P. et al. Effect of inhaled nitric oxide on normal human left ventricular function. J. Am. Coll. Cardiol. 1997; 30: 49-56.
  79. Bhorade S., Christenson J., O'Connor M. et al. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am. J. Respir. Crit. Care Med. 1999; 159: 571-579.
  80. Wagner F., Dandel M., Giinther G. et al. Nitric oxide inhalation in treatment of right ventricular dysfunction following left ventricular assist device implantation. Circulation 1997; 96 (supl. II): 291-296.
  81. Кассиль В. Л., Золотокрылина Е. С. Острый респираторный дистресс-синдром. М.: Медицина; 2003.
  82. Tamura M., Kurumatani H., Matsushita T. Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(l), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. Vestn. Khir. Im. 1.1. Grek. 2001; 160 (1): 77-79.
  83. Heerdt P. M., Weiss С. I. Prostaglandin El and intrapulmonary shunt in cardiac surgical patients with pulmonary hypertension. Ann. Thorac. Surg. 1990; 49 (3): 463-465.
  84. Blanch L., Van der Kloot T. E., Youngblood A. M. et al. Application of tracheal gas insufflation to acute unilateral lung injury in an experimental model. Am. J. Respir. Crit. Care Med. 2001; 164 (4): 642-647.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies